Kwon Kyungyoon J, Siliciano Robert F
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Howard Hughes Medical Institute, Baltimore, Maryland, USA.
J Clin Invest. 2017 Jun 30;127(7):2536-2538. doi: 10.1172/JCI95329. Epub 2017 Jun 19.
While antiretroviral therapy (ART) can reduce HIV-1 to undetectable levels, the virus generally reappears if treatment is stopped. Resurgence of the virus is due to the reactivation of T cells harboring latent integrated provirus, and recent studies indicate that proliferation of these latently infected cells helps maintain the HIV-1 reservoir. In this issue of the JCI, Lee et al. evaluated CD4+ T cell subsets to determine whether certain populations are more likely to harbor full-length, replication-competent provirus. The authors identified an enrichment of clonally expanded Th1 cells containing intact HIV-1 proviruses, suggesting that this polarized subset contributes to the persistence of the reservoir. Strategies to target these provirus-harboring cells need to be considered for future therapies aimed toward HIV-1 cure.
虽然抗逆转录病毒疗法(ART)可将HIV-1降低到检测不到的水平,但如果停止治疗,病毒通常会再次出现。病毒的复发是由于携带潜伏整合前病毒的T细胞重新激活,最近的研究表明,这些潜伏感染细胞的增殖有助于维持HIV-1储存库。在本期《临床研究杂志》中,Lee等人评估了CD4+T细胞亚群,以确定某些群体是否更有可能携带全长、具有复制能力的前病毒。作者发现含有完整HIV-1前病毒的克隆扩增Th1细胞有所富集,这表明这个极化亚群有助于储存库的持续存在。对于未来旨在治愈HIV-1的疗法,需要考虑针对这些携带前病毒细胞的策略。